WO2007144882A3 - Targeted chimeric proteins - Google Patents

Targeted chimeric proteins Download PDF

Info

Publication number
WO2007144882A3
WO2007144882A3 PCT/IL2007/000715 IL2007000715W WO2007144882A3 WO 2007144882 A3 WO2007144882 A3 WO 2007144882A3 IL 2007000715 W IL2007000715 W IL 2007000715W WO 2007144882 A3 WO2007144882 A3 WO 2007144882A3
Authority
WO
WIPO (PCT)
Prior art keywords
chimeric proteins
chimeric protein
moiety
cell
targeted chimeric
Prior art date
Application number
PCT/IL2007/000715
Other languages
French (fr)
Other versions
WO2007144882A2 (en
Inventor
Haya Lorberboum-Galski
Inna Grodzovski
Original Assignee
Yissum Res Dev Co
Haya Lorberboum-Galski
Inna Grodzovski
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yissum Res Dev Co, Haya Lorberboum-Galski, Inna Grodzovski filed Critical Yissum Res Dev Co
Publication of WO2007144882A2 publication Critical patent/WO2007144882A2/en
Publication of WO2007144882A3 publication Critical patent/WO2007144882A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6467—Granzymes, e.g. granzyme A (3.4.21.78); granzyme B (3.4.21.79)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

A chimeric protein comprising a cell targeting moiety and a cell killing moiety, wherein the cell killing moiety induces alternative programmed cell death. Also disclosed is a method for treating a subject suffering from a disease involving cells which are multi-drug resistant. The method comprises administrating to the subject a pharmaceutical composition comprising the aforementioned chimeric protein.
PCT/IL2007/000715 2006-06-14 2007-06-13 Targeted chimeric proteins WO2007144882A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81352806P 2006-06-14 2006-06-14
US60/813,528 2006-06-14

Publications (2)

Publication Number Publication Date
WO2007144882A2 WO2007144882A2 (en) 2007-12-21
WO2007144882A3 true WO2007144882A3 (en) 2008-07-03

Family

ID=38461912

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IL2007/000715 WO2007144882A2 (en) 2006-06-14 2007-06-13 Targeted chimeric proteins

Country Status (1)

Country Link
WO (1) WO2007144882A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006294663B2 (en) 2005-09-26 2012-03-22 Medarex, Inc. Human monoclonal antibodies to CD70
ITBG20120050A1 (en) * 2012-10-29 2013-01-28 Michele Mutti FUSION PROTEIN WITH PROTEASIC ACTIVITY AND SPECIFICITY OF ANTIBODIES

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999045128A2 (en) * 1998-03-02 1999-09-10 Yissum Research Development Company Of The Hebrew University Of Jerusalem Chimeric proteins with cell-targeting specificity and apoptosis-dinducing activities
US20030086919A1 (en) * 2001-07-17 2003-05-08 Rosenblum Michael G. Therapeutic agents comprising pro-apoptotic proteins

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999045128A2 (en) * 1998-03-02 1999-09-10 Yissum Research Development Company Of The Hebrew University Of Jerusalem Chimeric proteins with cell-targeting specificity and apoptosis-dinducing activities
US20030086919A1 (en) * 2001-07-17 2003-05-08 Rosenblum Michael G. Therapeutic agents comprising pro-apoptotic proteins

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JOHNSTONE RICKY W ET AL: "P-glycoprotein protects leukemia cells against caspase-dependent, but not caspase-independent, cell death", BLOOD, vol. 93, no. 3, 1 February 1999 (1999-02-01), pages 1075 - 1085, XP002450945, ISSN: 0006-4971 *
LIEBERMAN J ET AL: "Nuclear war: the granzyme A-bomb", CURRENT OPINION IN IMMUNOLOGY, ELSEVIER, OXFORD, GB, vol. 15, no. 5, October 2003 (2003-10-01), pages 553 - 559, XP004457013, ISSN: 0952-7915 *

Also Published As

Publication number Publication date
WO2007144882A2 (en) 2007-12-21

Similar Documents

Publication Publication Date Title
WO2008036841A3 (en) Tripartite oligonucleotide complexes and methods for gene silencing by rna interference
WO2007007173A3 (en) Human anti-madcam antibodies
WO2012075040A3 (en) mRNA FOR USE IN TREATMENT OF HUMAN GENETIC DISEASES
WO2007071777A3 (en) Immuno-rna-constructs
WO2007095316A3 (en) Compositions and methods for oligonucleotide formulations
WO2008076954A3 (en) Heterocycle compounds and methods of use thereof
WO2007091250A3 (en) Enzyme replacement therapy for treating lysosomal storage diseases
WO2007022470A3 (en) Methods and compositions for treating neurological disease
TR201000668T1 (en) POLYPEPTIDE-NUCLEIC ACID CONJUGATE FOR IMMUNOPROPHILACY OR IMMUNOTHERAPY FOR NEOPLASTIC OR INFECTIOUS DISORDERS
WO2007030680A3 (en) Triazole derivatives useful as axl inhibitors
EP1871910A4 (en) Compositions and methods for enhancing drug sensitivity and treating drug resistant infections an diseases
FR2909379B1 (en) NOVEL HETEROCYCLIC DERIVATIVES, PROCESS FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME.
WO2007065010A3 (en) Anti-angiogenesis compounds
WO2010009478A3 (en) Compositions and methods for treating disorders associated with overweight animals
WO2005090393A3 (en) Multimeric protein toxins to target cells having multiple identifying characteristics
WO2008070666A3 (en) Compositions and methods to treat cancer with cpg rich dna and cupredoxins
WO2008063511A3 (en) Methods for treating pompe disease
WO2005042692A3 (en) A method of inhibiting the expression of genes which mediate cellular cholesterol influx in animal cells and inhibiting the production of proteins resulting from the expression of such genes using cholesterol absorption inhibitors
WO2008103920A3 (en) Targeted protein cages
WO2010034015A3 (en) Modulating the alternative complement pathway
WO2007109155A3 (en) Assays for detection of antibodies to lysosomal enzymes
WO2008027739A3 (en) Antibodies to ntb-a
CL2007002376A1 (en) COMPOUNDS DERIVED FROM REPLACED PIRROL; PREPARATION PROCESS; PHARMACEUTICAL COMPOSITION; AND USE IN BACTERIAL DISEASES.
WO2009071689A3 (en) 5-halogen-substituted oxindole derivatives and use thereof for treating vasopressine-dependent diseases
WO2008013966A3 (en) Use of 8-quinolinol and its analogs to target cancer stem cells

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07736455

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 07736455

Country of ref document: EP

Kind code of ref document: A2